Abstract：Objective: To investigate the clinical value of platelet associated antibodies (PA-Ig) in evaluating the therapeutic effect on children with immune thrombocytopenia (ITP). Methods: A study from February 2020 to February 2023 was conducted. 104 children with ITP (observation group) and 22 healthy children (control group) were selected as the study subjects. Children in the observation group were divided into the complete response group, the effective group, and the ineffective group based on the treatment outcomes. All children were tested for PA-Ig levels. Results: Among the 104 children in the observation group, 85 (81.73%) achieved complete response (complete response group), 11 (10.58%) showed effectiveness (effective group), and the remaining 8 (7.69%) were ineffective (ineffective group). PA-IgG, PA-IgM, and PA-IgA levels in the observation group were lower than those in the control group (P<0.05). In the complete response group, PA-IgG, PA-IgM, and PA-IgA levels were lower than in the effective and ineffective groups. The effective group had lower levels compared to the ineffective group. There were statistically significant differences in PA-IgG, PA-IgM, and PA-IgA levels among the three groups with different treatment outcomes (P<0.05). Conclusion: Testing PA-Ig levels in pediatric ITP patients is beneficial for tailoring treatment and assessing early efficacy, reducing the risk of treatment, and has certain value in the evaluation of treatment outcomes in pediatric ITP patients.
刘娜, 白涛敏, 李瑞, 韩田田, 马芳芳, 林博浩. 血小板相关抗体在儿童免疫性血小板减少症治疗效果评估中的临床价值[J]. 河北医学, 2024, 30(1): 80-83.
LIU Na, BAI Taomin, LI Rui, et al. Clinical Value of Platelet Associated Antibodies in Evaluating the Therapeutic Effect on Children with Immune Thrombocytopenia. HeBei Med, 2024, 30(1): 80-83.
2024, Vol. 30 
冀公网安备13080202000677号